| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1471-4159.1977.TB10721.X |
| P698 | PubMed publication ID | 591956 |
| P2093 | author name string | P. Böhlen | |
| P. J. Schechter | |||
| B. W. Metcalf | |||
| B. Lippert | |||
| M. J. Jung | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 797-802 | |
| P577 | publication date | 1977-11-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice | |
| P478 | volume | 29 |
| Q33892509 | 4-aminobutyrate aminotransferase (ABAT): genetic and pharmacological evidence for an involvement in gastro esophageal reflux disease |
| Q42169038 | 5-Fluoromethylornithine, an irreversible and specific inhibitor of L-ornithine:2-oxo-acid aminotransferase |
| Q68508079 | ?-Vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice |
| Q68742320 | A controlled study of oral vigabatrin (gamma-vinyl GABA) in patients with cerebellar ataxia |
| Q42540010 | A novel strategy for the treatment of cocaine addiction |
| Q48133716 | Abundant GABAergic innervation of rat posterior pituitary revealed by inhibition of GABA-transaminase |
| Q57098730 | Activity-dependent γ-aminobutyric acid release controls brain cortical tissue slice metabolism |
| Q48906093 | Acute effects of sodium valproate and gamma-vinyl GABA on regional amino acid metabolism in the rat brain: incorporation of 2-[14C]glucose into amino acids |
| Q46320031 | Alterations of GABA metabolism and seizure susceptibility in the substantia nigra of the kindled rat acclimating to changes in osmotic state |
| Q42271598 | Amygdaloid kindling and the GABA system |
| Q44516499 | Analgesia and hyperalgesia from GABA-mediated modulation of the cerebral cortex |
| Q34394976 | Antiepileptic drug mechanisms of action |
| Q41553644 | Benzodiazepine antagonists abolish electrophysiological effects of sodium valproate in the rat |
| Q43264900 | Binasal visual field defects are not specific to vigabatrin |
| Q39625389 | Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, ?-acetylenic GABA (4-amino-hex-5-ynoic acid) and ?-vinyl GABA (4-amino-hex-5-enoic acid) |
| Q41440975 | Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport. |
| Q49059061 | Carnosine and anserine homeostasis in skeletal muscle and heart is controlled by β-alanine transamination |
| Q48846886 | Chronic elevation of brain GABA by ?-vinyl GABA treatment does not alter the sensitivity of GABAergic or dopaminergic receptors in rat CNS |
| Q34038018 | Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor |
| Q41976215 | Clinical and biochemical effects of gamma-vinyl Gaba in tardive dyskinesia |
| Q38671473 | Clinical pharmacology of vigabatrin |
| Q37815377 | Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms |
| Q37948429 | Clinical relevance of measuring GABA concentrations in cerebrospinal fluid |
| Q34420834 | Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs |
| Q33855027 | Co-release of acetylcholine and gamma-aminobutyric acid by a retinal neuron |
| Q73583786 | Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin |
| Q71796824 | Determination of the R(-)- and S(+)-enantiomers of gamma-vinyl-gamma-aminobutyric acid in human body fluids by gas chromatography--mass spectrometry |
| Q48889003 | Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy |
| Q48158635 | Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma |
| Q74826593 | Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-guanidinobutyric acid--an effect of vigabatrin treatment? |
| Q34054805 | Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy |
| Q54431796 | Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. |
| Q38115721 | Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs |
| Q66974712 | Dyskinetic effects of intrastriatally injected GABA-transaminase inhibitors |
| Q43177230 | Effect of chronic treatment with the GABA transaminase inhibitors gamma-vinyl GABA and ethanolamine O-sulphate on the in vitro GABA release from rat hippocampus |
| Q33630508 | Effect of vigabatrin (gamma-vinyl GABA) on amino acid levels in CSF of epileptic patients |
| Q33591417 | Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems |
| Q70953090 | Effect of γ-vinyl GABA on bicuculline-induced seizures |
| Q43429100 | Effects of Vigabatrin (γ-vinyl GAB A) on Neuro transmission-Related Amino Acids and on GAB A nd Benzodiazepine Receptor Binding in Rats |
| Q72427036 | Effects of adrenalectomy and corticosteroids on three enzymes involved in amino acid metabolism in the brain of adult and newborn rats |
| Q43646150 | Effects of anticonvulsants on cholinergic and GABAergic properties in the neuronal cell clone NG108-15. |
| Q37185374 | Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats |
| Q48863489 | Effects of chronic oral treatment with GABA-transaminase inhibitors on the GABA system in brain, liver, kidney, and plasma of the rat. |
| Q41690460 | Effects of ethanolamine-O-sulphate and ?-acetylenic-GABA on GABA content, GAD and GABA-T in various areas of chick brain after intraventricular microinjection |
| Q44009053 | Effects of gamma-vinyl GABA (vigabatrin) on blood pressure and body weight of hypertensive and normotensive rats |
| Q48235568 | Effects of increasing doses of vigabatrin on platelet gamma-aminobutyric acid-transaminase and brain gamma-aminobutyric acid in rats |
| Q48574637 | Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine |
| Q48637386 | Effects of physostigmine, paraoxon and soman on brain GABA level and metabolism |
| Q43718365 | Effects of radiofrequency exposure on the GABAergic system in the rat cerebellum: clues from semi-quantitative immunohistochemistry |
| Q41891059 | Effects of single and multiple increasing doses of vigabatrin on brain gaba metabolism and correlation with vigabatrin plasma concentration |
| Q48611683 | Effects of substantia nigra γ-vinyl-GABA infusions on flurothyl seizures in adult rats |
| Q34722740 | Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system |
| Q35812640 | Effects of vigabatrin, an irreversible GABA transaminase inhibitor, on ethanol reinforcement and ethanol discriminative stimuli in mice |
| Q37754477 | Emerging drugs for partial onset seizures. |
| Q38769191 | Emerging roles of Na⁺/H⁺ exchangers in epilepsy and developmental brain disorders |
| Q46510543 | Endogenous concentrations, pharmacokinetics, and selected pharmacodynamic effects of a single dose of exogenous GABA in horses |
| Q35061649 | Ethanol, not detectably metabolized in brain, significantly reduces brain metabolism, probably via action at specific GABA(A) receptors and has measureable metabolic effects at very low concentrations |
| Q36942147 | Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy |
| Q70657123 | Evidence for the involvement of a GABA-mediated inhibition in the hypovolaemia-induced vasopressin release |
| Q48455904 | Experimental febrile convulsions in epileptic chickens: the anticonvulsant effect of elevated gamma-aminobutyric acid concentrations |
| Q33723355 | Failure of ischemic neuroprotection by potentiators of gamma-aminobutyric acid |
| Q54130707 | GABA agonists in cebus monkeys with neuroleptic-induced persistent dyskinesias. |
| Q70942576 | GABA levels and synthesis index in different brain areas of two obese rat models |
| Q34528008 | GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings |
| Q37775215 | GABAB receptors in reward processes |
| Q41642418 | Gabaculine and isogabaculine: biochemistry and pharmacology in mice |
| Q41573192 | Gabaergic modulation of mouse-killing in the rat. |
| Q43183029 | Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy |
| Q28579393 | Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats |
| Q73052698 | Glutamate receptor activation induces carrier mediated release of endogenous GABA from rat striatal slices |
| Q42631792 | Hypotensive and sedative properties of alpha-adrenoceptor agonists: relation to pre- and post-synaptic stimulation [proceedings] |
| Q36101368 | Imaging addiction with PET: is insight in sight? |
| Q44301347 | Immunohistochemistry as a tool for topographical semi-quantification of neurotransmitters in the brain |
| Q71864838 | Immunologic Aspects of Vigabatrin Treatment in Epileptic Children |
| Q41112028 | Important pharmacokinetic properties of antiepileptic drugs |
| Q38662848 | In Vivo Detection of CPP-115 Target Engagement in Human Brain |
| Q72434035 | Increased CSF gamma-aminobutyric acid after treatment with gamma-vinyl GABA |
| Q43976828 | Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat. |
| Q42103297 | Induction of analgesia and morphine potentiation by irreversible inhibitors of GABA-transaminase [proceedings] |
| Q88404568 | Infantile Spasms-Have We Made Progress? |
| Q46011245 | Influence of agmatine on the protective action of numerous antiepileptic drugs against pentetrazole-induced seizures in mice. |
| Q45879146 | Inhibition of aminotransferase enzyme systems by gabaculine |
| Q41504576 | Inhibition of brain glutamate decarboxylase by 2-keto-4-pentenoic acid, a metabolite of allylglycine |
| Q34417684 | Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug |
| Q39805656 | Inhibitors of GABA metabolism |
| Q38742554 | Insular Cortex is Critical for the Perception, Modulation, and Chronification of Pain |
| Q48161275 | Interrelationships between ornithine, glutamate, and GABA. II. Consequences of inhibition of GABA-T and ornithine aminotransferase in brain |
| Q36096461 | Intravenous bicuculline in mice facilitates in vivo evaluation of drugs affecting GABA like mechanisms [proceedings] |
| Q72488448 | Intravenous bicuculline test in mice: Characterization with gabaergic drugs |
| Q36096999 | Investigation of the antifibrillatory activity of some anticonvulsant gamma-aminobutyric acid-transaminase inhibitors in the rabbit isolated heart: comparison with phenytoin and mexiletine |
| Q70996469 | Invivo inactivation of γ-aminobutyric acid-α-ketoglutarate transaminase by 4-amino-5-fluoropentanoic acid |
| Q41892034 | Ion channel expression by white matter glia: The O-2A glial progenitor cell |
| Q42209420 | Irreversible inhibition of GABA-T by halogenated analogues of beta-alanine |
| Q48597564 | Lack of association between vigabatrin and impaired cognition |
| Q45103257 | Long-term evaluation of vigabatrin (gamma vinyl GABA) in epilepsy |
| Q37731488 | Management of epilepsy in drug-resistant patients. |
| Q48946257 | Measurement of release of endogenous GABA and catabolites of [3H]GABA from synaptosomal preparations using ion-exchange chromatography |
| Q32066867 | Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin |
| Q37953574 | Mechanism of action of vigabatrin: correcting misperceptions |
| Q41147357 | Metabolic inhibitors and subcellular distribution of GABA |
| Q72434049 | Mexiletine for control of ventricular dysrhythmias in pregnancy |
| Q44233535 | Modulation of the in vivo effects of gabapentin by vigabatrin and SKF89976A. |
| Q24683346 | Molecular targets for antiepileptic drug development |
| Q48713620 | Neurochemical actions of vigabatrin and tiagabine alone and in combination in mouse cortex |
| Q35617513 | Neuronal gamma-aminobutyric acid (GABA) type A receptors undergo cognate ligand chaperoning in the endoplasmic reticulum by endogenous GABA. |
| Q35074280 | Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate |
| Q45753096 | Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase |
| Q48903818 | Open, double-blind and long-term study of vigabatrin in chronic epilepsy |
| Q71050715 | Paradoxical blockade of a muscimol response by thip, a GABA agonist and also by GABA-transaminase inhibitors |
| Q38261962 | Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions. |
| Q42055649 | Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans |
| Q45138847 | Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis |
| Q36020907 | Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships |
| Q52294783 | Pharmacological studies on stimulation-produced analgesia in mice |
| Q40126469 | Pharmacology of GABA-mediated inhibition of spinal cord neurons in vivo and in primary dissociated cell culture |
| Q36223272 | Pharmacology of Vigabatrin |
| Q33941151 | Placental transfer of vigabatrin (gamma-vinyl GABA) and its effect on concentration of amino acids in the embryo of TO mice |
| Q28348767 | Plasticity of rat central inhibitory synapses through GABA metabolism |
| Q48500920 | Polyamine reutilization and turnover in brain |
| Q44531006 | Positron emission tomography studies of potential mechanisms underlying phencyclidine-induced alterations in striatal dopamine |
| Q60919921 | Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects |
| Q68093037 | Prospects for new drug treatment in epilepsy: a review |
| Q33425343 | Protection by 4-amino-hex-5-enoic acid (?-vinyl GABA) and hypobaric hypoxia against kainic acid neurotoxicity |
| Q45304013 | Quantitative evaluation of functional capacity during isoniazid therapy in huntington's disease |
| Q37216876 | Racemic gamma vinyl-GABA (R,S-GVG) blocks methamphetamine-triggered reinstatement of conditioned place preference. |
| Q66985834 | Rapid method for the assay of 4-aminobutyric acid (GABA), glutamic acid and aspartic acid in brain tissue and subcellular fractions |
| Q51586661 | Reduction of Plasma Alanine Aminotransferase During Vigabatrin Treatment |
| Q36596183 | Regulation of glucagon secretion in normal and diabetic human islets by γ-hydroxybutyrate and glycine |
| Q48790674 | Regulation of the GABAA receptor/ion channel complex by intracellular GABA levels |
| Q66930817 | Regulatory interrelations between GABA and polyamines. I. Brain GABA levels and polyamine metabolism |
| Q48660215 | Relationship between platelet and brain GABA transaminase inhibition by single and multiple doses of vigabatrin in rats |
| Q72051939 | Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment |
| Q73426207 | Reversal of the activity-dependent suppression of GABA-mediated inhibition in hippocampal slices from gamma-vinyl GABA (vigabatrin)-pretreated rats |
| Q34504231 | Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group |
| Q48281449 | Stereoselective uptake of the GABA-transaminase inhibitors gamma-vinyl GABA and gamma-acetylenic GABA into neurons and astrocytes |
| Q48119406 | Studies on Glutamate Decarboxylase of the Mammalian Brain |
| Q48676195 | Synergistic anticonvulsant effects of GABA-T inhibitors and glycine |
| Q40614956 | The development of epilepsy in the paediatric brain |
| Q48268451 | The effect of 2-amino-3-arsonopropionate and 2-amino-4-arsonobutyrate on the development and maintenance of amygdala kindled seizures |
| Q34396886 | The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients |
| Q42027362 | The effect of vigabatrin on brain and platelet GABA-transaminase activities |
| Q67875664 | The effect of vigabatrin on central nervous system oxygen toxicity in rats |
| Q34305846 | The mechanisms of action of commonly used antiepileptic drugs |
| Q48925359 | The rate of turnover of cortical GABA from [1-13C]glucose is reduced in rats treated with the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA). |
| Q41611534 | The relationship between GABA concentrations in brain and cerebrospinal fluid |
| Q27692644 | Tonic GABAA Receptors as Potential Target for the Treatment of Temporal Lobe Epilepsy |
| Q40085062 | Transport and Metabolism of Glutamate and Gaba in Neurons and Glial Cells |
| Q37620193 | Treatment of refractory complex partial seizures: role of vigabatrin |
| Q48404047 | Type I and II metabotropic glutamate receptors regulate the outflow of [3H]D-aspartate and [14C]gamma-aminobutyric acid in rat solitary nucleus. |
| Q67275212 | Vigabatrin |
| Q73210511 | Vigabatrin |
| Q83791551 | Vigabatrin |
| Q48552376 | Vigabatrin 35 years later - from mechanism of action to benefit-risk considerations |
| Q24562060 | Vigabatrin and psychosis |
| Q56832845 | Vigabatrin dosing during haemodialysis |
| Q48486105 | Vigabatrin enhances promoted release of GABA in neonatal rat optic nerve |
| Q37848404 | Vigabatrin for infantile spasms |
| Q54420209 | Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study. |
| Q28486250 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex |
| Q37953578 | Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States |
| Q27308034 | Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms |
| Q54030471 | Vigabatrin treatment in children. |
| Q36676442 | Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control |
| Q48279488 | Vigabatrin: a three year clinical analysis |
| Q36735101 | Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy |
| Q36942736 | Vigabatrin: rational treatment for chronic epilepsy |
| Q51744399 | Visual field defect during therapy with valproic-acid. |
| Q44812822 | gamma-Hydroxybutyric acid in subcellular fractions of rat brain |
| Q41634666 | gamma-Vinyl GABA: effects of chronic administration on the metabolism of GABA and other amino compounds in rat brain |
| Q51403215 | gamma-aminobutyric acid mimetic drugs differentially inhibit the dopaminergic response to cocaine. |
Search more.